According to the announcement from Shengda Bio-Pharm (603079.SH), the company expects to achieve a net profit attributable to the owners of the parent company of between 26 million yuan and 36 million yuan for the year 2024, marking a turnaround from a loss compared to the same period last year (statutory disclosure data).

During the reporting period, the company focused on refined management and technological improvements, achieving cost reduction and efficiency enhancement. At the same time, the company deepened its differentiated competition strategy, intensifying its market development efforts for pharmaceutical-grade vitamins and clean label products, resulting in an optimized sales structure compared to the same period last year. During the reporting period, the operating income of the company's pharmaceutical-grade vitamin products and clean label products, among other high-value products, increased year-on-year